Recent News

• 03.04.2025 - FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
• 02.27.2025 - FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
• 02.05.2025 - FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
• 12.30.2024 - FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

Recent Filings

• 02.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - EFFECT Notice of Effectiveness
• 02.07.2025 - 8-K Current report
• 02.03.2025 - S-3 Registration statement under Securities Act of 1933
• 01.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.24.2025 - 8-K Current report
• 01.21.2025 - EFFECT Notice of Effectiveness
• 01.17.2025 - POS AM Post-Effective amendments for registration statement
• 01.14.2025 - 424B4 Prospectus [Rule 424(b)(4)]